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Abstract
Background: Chaperone-mediated autophagy (CMA) is a selective autophagy-lysosome protein degradation pathway. The
role of CMA in normal neuronal functions and in neural disease pathogenesis remains unclear, in part because there is no
available method to monitor CMA activity at the single-cell level.
Methodology/Principal Findings: We sought to establish a single-cell monitoring method by visualizing translocation of
CMA substrates from the cytosol to lysosomes using the HaloTag (HT) system. GAPDH, a CMA substrate, was fused to HT
(GAPDH-HT); this protein accumulated in the lysosomes of HeLa cells and cultured cerebellar Purkinje cells (PCs) after
labeling with fluorescent dye-conjugated HT ligand. Lysosomal accumulation was enhanced by treatments that activate
CMA and prevented by siRNA-mediated knockdown of LAMP2A, a lysosomal receptor for CMA, and by treatments that
inactivate CMA. These results suggest that lysosomal accumulation of GAPDH-HT reflects CMA activity. Using this method,
we revealed that mutant cPKC, which causes spinocerebellar ataxia type 14, decreased CMA activity in cultured PCs.
Conclusion/Significance: In the present study, we established a novel fluorescent-based method to evaluate CMA activity
in a single neuron. This novel method should be useful and valuable for evaluating the role of CMA in various neuronal
functions and neural disease pathogenesis.
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Introduction
In neurons, removal of misfolded proteins by protein degrada-
tion systems is important for various neuronal functions and
survival. There are two major protein degradation systems: the
ubiquitin-proteasome system (UPS) and the autophagy-lysosome
system, which primarily degrade short-lived and long-lived
proteins, respectively. The autophagy-lysosome system consists of
three pathways: macroautophagy, microautophagy and chaper-
one-mediated autophagy (CMA). In neurodegenerative diseases,
age-related decline in intracellular protein degradation is consid-
ered to cause accumulation and aggregation of misfolded protein
in neurons, leading to neurodegeneration [1,2]. This accumulation
triggers additional impairment of protein degradation systems,
resulting in further accumulation of misfolded proteins and
additional neurodegeneration [3]. Accumulating evidence has
revealed that UPS and macroautophagy are important for the
clearance of misfolded proteins in neurons and are related to the
pathogenesis of some neurodegenerative diseases [4,5]. CMA is
involved in the degradation of approximately 30% of cytosolic
proteins and oxidized proteins [6,7], suggesting that CMA
contributes to protein quality control in neurons. Although there
are several reports concerning CMA in Parkinson’s disease
[8,9,10,11] and Alzheimer’s disease [12,13], the role of CMA in
various neuronal functions and in other neurodegenerative
diseases remains unknown. In neurons, CMA has been less
studied than UPS and macroautophagy in part because there is
neither an available protein marker to monitor CMA activity nor a
method to evaluate CMA activity at the single-cell level. To
overcome this problem, we sought to establish a novel fluores-
cence-based method to monitor CMA activity at the single cell
level and to evaluate CMA activity in primary cultured neurons.
Spinocerebellar ataxia type 14 (SCA14) is an autosomal
dominant neurodegenerative disorder that is clinically character-
ized by symptoms of cerebellar dysfunction and is caused by
missense or deletion mutations in the PRKCG gene encoding
protein kinase Cc (cPKC) [14,15,16]. We previously demonstrat-
ed that mutant versions of cPKC form aggregates in cultured cells
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31232[17] and mouse primary cultured Purkinje cells (PCs) [18], leading
to impairment of UPS and apoptotic cell death [19], as in other
neurodegenerative diseases. We have also shown that mutant
cPKC induces improper development of PC dendrites in an
aggregate-independent manner [18]. Furthermore, mutant cPKC
has aberrant kinase activities, higher basal activity in the cytosol
and lower activity at the plasma membrane when activated
[20,21]. These findings suggest that mechanisms other than
aggregation could participate in the neurodegeneration of
cerebellar Purkinje cells in SCA14. To clarify the aggregate-
independent mechanism, we used our newly established method
for monitoring CMA to investigate whether mutant cPKC affects
CMA activity in primary cultured PCs.
Results
Single-cell monitoring of CMA activity by visualizing
lysosomal accumulation of a CMA substrate using the
HaloTag system
In the process of CMA, cytosolic substrate proteins for CMA
are recognized by heat shock cognate protein 70 (Hsc70), a
molecular chaperone. The substrates are then transferred to the
lysosome, where they are translocated through lysosome-associat-
ed membrane protein type 2A (LAMP2A) and subsequently
degraded by lysosomal proteases [6]. Translocation of CMA
substrates from the cytosol to lysosomes is a crucial step in CMA
and thus indicates CMA activity. To monitor CMA activity at the
single-cell level, we visualized the translocation of a CMA
substrate from the cytosol to lysosomes using the HaloTag (HT)
system [22]. HT-fused proteins produced in cells can be labeled by
brief extracellular application of a fluorescently labeled HT ligand.
When HT-fused proteins are exposed to an HT ligand, the HT
covalently binds the HT ligand at neutral pH (cytosol and nucleus)
but does not bind in the acidic lysosome, suggesting that only
extralysosomal proteins are labeled by a fluorescent HT ligand
(Fig. 1A). However, when HT-fused proteins are fluorescently
labeled in the cytosol and translocated to lysosomes after further
cultivation, the fluorescent labels (tetramethylrhodamine (TMR)
and Oregon green (OG)) continue to fluoresce (Fig. 1B). Using this
property, we sought to monitor the translocation of GAPDH, a
well-known CMA substrate [6], from the cytosol to lysosomes.
GAPDH fused to HT (GAPDH-HT) was expressed in HeLa
cells using adenoviral vectors (Fig. S1), and cells were incubated
10 min with a TMR-labeled HT ligand (TMR-HT ligand).
Immediately after labeling, TMR-labeled GAPDH-HT was
uniformly distributed in the cytoplasm, but 21 h of additional
incubation led to dot-like cytoplasmic accumulations of GAPDH-
HT in several cells (Fig. 1C). Immediately after labeling, GAPDH-
HT did not colocalize with immunostained LAMP2, a lysosomal
marker protein (Fig. 1D, upper), suggesting that only extralyso-
somal GAPDH-HT was labeled with the TMR-HT ligand. In
contrast, the dot-like accumulations of GAPDH-HT after further
incubation strongly colocalized with LAMP2 (Fig. 1D, lower).
Furthermore, these dot-like accumulations of GAPDH-HT,
labeled with OG-HT ligand, strongly colocalized with Lyso-
Tracker-red, a fluorescent lysosomal marker (Fig. 1E). These
results indicate that translocation of GAPDH-HT to lysosomes can
be visualized using the HT system.
Next, we examined whether this translocation is mediated by
CMA. Mammalian LAMP2, which is localized in the lysosomal
membrane, consists of three splicing isoforms (LAMP2A, B, C)
that are alternatively spliced in their carboxyl termini [23]. Among
the isoforms, only LAMP2A is involved in CMA as a lysosomal
receptor for CMA substrates [24]. Most dots of GAPDH-HT were
colocalized with LAMP2A-specific antibody staining (Fig. 1F),
indicating that GAPDH-HT accumulates in lysosomes containing
LAMP2A. Next, we examined whether lysosomal translocation of
GAPDH-HT would occur in HeLa cells with siRNA-mediated
knockdown of LAMP2A. We designed a LAMP2A-siRNA that
targets an RNA sequence corresponding to the carboxyl terminus
of LAMP2A, which is unique to LAMP2A and absent in other
LAMP2 isoforms. Transfection with LAMP2A-siRNA nearly
abolished the expression of LAMP2A while only partially
decreasing the amount of total LAMP2 (Fig. S2A,B), suggesting
that LAMP2A-siRNA specifically targets and decreases LAMP2A
among the three LAMP2 isoforms. Compared to nontargeting
control siRNA, LAMP2A-siRNA significantly inhibited the dot-
like accumulation of GAPDH-HT in transfected cells (Fig. 2A–C).
Furthermore, CMA is reported to be activated by various stimuli,
including long-term serum deprivation [25], oxidative stress [7]
and mycophenolic acid (MPA), which decrease intracellular GTP
levels [26]. Therefore, we monitored the translocation of GAPDH-
HT in the presence or absence of these treatments for 21 h
following labeling with the TMR-HT ligand. The proportion of
cells showing dot-like accumulations of GAPDH-HT was
significantly increased by serum deprivation, 100 mMH 2O2 and
10 mM MPA (Fig. 2D,E). In addition, the number of dots per cell
was also increased by these treatments (Fig. 2F). In contrast, CMA
is inhibited by the inhibitors of p38 mitogen activated protein
kinase (MAPK) and by cycloheximide [27]. Indeed, lysosomal
translocation of GAPDH-HT was significantly inhibited by 20 mM
SB202190, a p38 MAPK inhibitor and 20 mg/ml cycloheximide
(Fig. 2D–F). These results indicate that CMA activity can be
assessed by monitoring lysosomal translocation of GAPDH-HT,
representing a novel method to evaluate CMA in individual cells.
Since macroautophagy is considered a nonselective protein
degradation pathway for cytosolic proteins, it is possible that
lysosomal accumulation of GAPDH-HT is mainly mediated by
macroautophagy, not by CMA. To exclude this possibility, we
examined lysosomal translocation of GAPDH-HT in cells treated
with siRNA against Atg5, which is essential for macroautophagy.
We confirmed that Atg5-siRNA decreased the amount of Atg5-
Atg12 complex and macroautophagy activity (Fig. S2). We also
examined the effects of 3-methyladenine (3-MA), which suppresses
macroautophagy by inhibiting type III phosphatidylinositol 3-
kinase [28], on translocation of GAPDH-HT. Lysosomal translo-
cation of GAPDH-HT was not affected by Atg5-siRNA or 10 mM
3-MA (Fig. S3A–D). Moreover, GAPDH-HT accumulated in
LAMP2A-positive lysosomes in embryonic fibroblast (MEF) cells
from Atg5-knockout (KO) mice (Fig. S3E). These findings suggest
that the lysosomal accumulation of GAPDH-HT is not mediated
by macroautophagy.
Macroautophagy is activated to compensate for CMA impair-
ment by LAMP2A knockdown [29]. In the present study,
LAMP2A-siRNA increased the dot-like immunostaining of LC3
and the amount of LC3-II, which is specifically localized to
autophagosomes [30] (Fig. S2), confirming that LAMP2A-siRNA
activated macroautophagy in HeLa cells. Interestingly, LAMP2A-
siRNA increased the abundance of the Atg5-Atg12 complex
detected with the anti-Atg5 antibody (Fig. S2), suggesting that
CMA affects macroautophagy activity by regulating Atg5-Atg12
complex levels. If GAPDH-HT accumulated in lysosomes by
macroautophagy, this accumulation would be stimulated by
LAMP2A-siRNA. However, accumulation was inhibited by
LAMP2A-siRNA. Moreover, dots of GAPDH-HT rarely coloca-
lized with dot-like immunostaining of LC3 even in the presence of
CMA activators, while they strongly colocalized with or were
surrounded by LAMP2A immunoreactivity (Fig. S4). Collectively,
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HT is mainly mediated by CMA and not by macroautophagy. We
therefore consider the observation of GAPDH-HT lysosomal
translocation a novel and valid method to evaluate CMA activity
at a single cell level.
Single-cell monitoring of CMA activity in primary
cultured cerebellar Purkinje cells
To investigate whether CMA activity could be assessed in
primary cultured neurons by the lysosomal-translocation method,
we expressed GAPDH-HT selectively in primary cultured
cerebellar Purkinje cells using adenoviral vectors (Fig. S1) [18].
Similar to HeLa cells, TMR-labeled GAPDH-HT was uniformly
distributed throughout PC somata and dendrites immediately after
labeling with the TMR-HT ligand. In contrast, most PCs had
many cytoplasmic dots of GAPDH-HT 24 h after labeling, with
dots being especially abundant in PC somata (Fig. 3A). These dots
also colocalized with LysoTracker and LAMP2 immunoreactivity
(Fig. 3B,C). In contrast to the results in HeLa cells, cytoplasmic
dots were observed in almost all PC somata. Therefore, we
quantitatively assessed CMA activity by counting the number of
dots per PC soma. The number of GAPDH-HT dots in PC
Figure 1. Visualization of CMA substrate translocation from cytosol to lysosomes using the HaloTag (HT) system. (A) Schematic
illustration of CMA substrate-HT labeling with the HT ligand fused to fluorescent dye (gray circle). CMA substrate-HT in cytosol can be labeled with
fluorescent dye since the HT reaction occurs at neutral pH. In contrast, CMA substrate-HT in lysosomes cannot be labeled since the HT reaction does
not occur at acidic pH. (B) Schematic illustration of CMA substrate-HT translocation from cytosol to lysosome. Because the fluorescent dyes used in
this study (TMR and OG) are not quenched at acidic pH, labeled CMA substrates can be visualized after translocation to lysosomes. (C) Representative
fluorescent images of TMR-labeled GAPDH-HT immediately after (0 h, upper) and 21 h after labeling (21 h, lower) with TMR-HT ligand in HeLa cells.
Arrows on the lower image indicate the cells with obvious GAPDH-HT dots. Bar=20 mm. (D) Representative GAPDH-HT fluorescence (left), LAMP2
immunostaining (center) and merged (right) images of HeLa cells immediately after (0 h, upper panels) and 21 h after labeling (21 h, lower panels)
with TMR-HT ligand. Bar=5 mm. (E) Representative GAPDH-HT fluorescence (left), LysoTracker red fluorescence (center) and merged (right) images of
HeLa cells 21 h after labeling with OG-HT ligand. Bar=5 mm. (F) Representative GAPDH-HT fluorescence (left), LAMP2A immunostaining (center) and
merged (right) images of HeLa cells 21 h after labeling with TMR-HT ligand. Bar=5 mm.
doi:10.1371/journal.pone.0031232.g001
A Novel Method to Evaluate CMA in a Single Neuron
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31232somata was significantly increased by the CMA activating stimuli,
100 mMH 2O2,1 0mM MPA and 1 mM 6-aminonicotinamide (6-
AN), which is also reported to activate CMA [27] (Fig. 3D,E).
Furthermore, we attempted to investigate whether siRNA-
mediated knockdown of LAMP2A inhibits lysosomal translocation
of GAPDH-HT in primary cultured neurons, as seen in HeLa
cells. For this purpose, we used cortical neurons, instead of
Purkinje cells, because it was difficult to knockdown LAMP2A in a
Purkinje cell-specific manner. We confirmed that knockdown of
LAMP2A significantly inhibited lysosomal translocation of
GAPDH-HT in primary rat cortical neurons (Fig. S5). These
results suggest that the lysosomal-translocation method can be
used to evaluate CMA activity in primary cultured neurons.
SCA14 mutant cPKC impairs CMA in HeLa cells and
primary cultured PCs
Using an HT pull-down assay, we identified Hsc70 as a
preferred binding protein for the SCA14 mutant cPKC in
Figure 2. Lysosomal translocation of GAPDH-HT reflects CMA activity in HeLa cells. (A) Representative fluorescent images of GAPDH-HT
21 h after labeling with TMR-HT ligand in HeLa cells transfected with nontargeting-siRNA (left) or LAMP2A-siRNA (right). Bar=20 mm. (B,C)
Quantitative analyses of GAPDH-HT lysosomal translocation in cells transfected with nontargeting (Non)- and LAMP2A-siRNA. (B) Cells having more
than 5 dots of GAPDH-HT were classified as GAPDH-HT dot-positive cells. We counted the number of GAPDH-HT dot-positive cells in 50–70 GAPDH-
HT-expressing cells. (C) We assessed the number of GAPDH-HT dots per cell. The percentage of GAPDH-HT dot-positive cells and the number of
GADPH-HT dots per cell were significantly decreased by siRNA-mediated LAMP2A-knockdown. ** p,0.001 vs cells treated with nontargeting-siRNA
(unpaired t-test, n=16 in B, n=57 for nontargeting-siRNA and n=74 for LAMP2A-siRNA in C). (D) Representative fluorescent images of GAPDH-HT
taken 21 h after labeling with the TMR-HT ligand in HeLa cells treated with vehicle (0.1% DMSO, 0.1% methanol, left upper), serum free medium (0.1%
DMSO, 0.1% methanol, center upper), H2O2 (100 mM, right upper), mycophenolic acid (MPA; 10 mM, left lower), SB202190 (20 mM, left center) or
cycloheximide (CHX; 20 mg/ml, right lower). Bar=20 mm. (E,F) Quantitative analyses of GAPDH-HT lysosomal translocation in cells treated with CMA
activators or inhibitors the percentages of GAPDH-HT dot-positive cells (E) and the number of GAPDH-HT dots per cell (F). Percentages of GAPDH-HT
dot-positive cells and the numbers of GAPDH-HT dots per cell were significantly increased by CMA activators (serum free medium, H2O2 and MPA),
while they were significantly decreased by CMA inhibitors (SB202190 and CHX). * p,0.01, ** p,0.001 vs cells treated with vehicle (unpaired t-test,
n=12 for cells treated with vehicle, n=8 for cells treated with CMA activators and inhibitors in E, n=96 for vehicle, n=61 for serum free, n=45 for
H2O2, n=58 for MPA, n=52 for SM202190 and n=41 for CHX in F).
doi:10.1371/journal.pone.0031232.g002
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confirmed by HT pull-down assay in cultured cell line (Fig.
S6B,C). Furthermore, 2-color fluorescence recovery after photo-
bleaching (FRAP) and raster image correlation spectroscopy
(RICS) analyses revealed that mutant cPKC-GFP interacted with
TMR-labeled Hsc70-HT, thereby reducing the mobility of
Hsc70-HT in living PCs (Table S1 and S2). As Hsc70 is involved
in CMA [6], it is possible that mutant cPKC affects CMA activity
in PCs. To explore this possibility, we evaluated lysosomal
translocation of GAPDH-HT in PC somata coexpressing wild
type (WT) or mutant cPKC-GFP without aggregation of the
mutant protein. Whereas WT cPKC-GFP did not affect
lysosomal translocation of GAPDH-HT compared with cells
expressing GFP alone (14.461.6 dots/soma, n=45), mutant
cPKC-GFP significantly decreased the number of GAPDH-HT
dots in PC somata (Fig. 4C, D). Similar results were obtained
using HeLa cells coexpressing cPKC-GFP and GAPDH-HT (Fig.
S7A,B). Furthermore, expression of mutant cPKC-GFP signifi-
cantly increased the amount of another CMA substrate, myocyte
enhancer factor 2D (MEF2D) (Fig. S7C,D) [10]. In addition,
oxidative stress (100 mMH 2O2) failed to increase the number of
GAPDH-HT dots in PC somata expressing mutant cPKC-GFP
but did significantly increase GAPDH-HT dots in PC somata
expressing WT cPKC-GFP (Fig. 4D). These results suggest that
mutant cPKC inhibits both basal and induced CMA activity in
primary cultured PCs.
Figure 3. Lysosomal translocation of GAPDH-HT in primary cultured PCs. (A) Representative fluorescent images of TMR-labeled GAPDH-HT
immediately after (0 h, left) and 24 h after labeling (24 h, right) with TMR-HT ligand in primary cultured PCs. Images were projected from a Z-stack of
images obtained by confocal laser microscopy. Bar=20 mm. (B) Representative GAPDH-HT fluorescence (left), LAMP2 immunostaining (center) and
merged (right) images of PC somata 21 h after labeling with TMR-HT ligand. Images were taken from the center of the Z-stack. Bar=5 mm. (C)
Representative GAPDH-HT fluorescence (left), LysoTracker red fluorescence (center) and merged (right) images of PC somata 21 h after labeling with
TMR-OG ligand. Bar=5 mm. (D) Representative fluorescent images of GAPDH-HT in PC somata treated with vehicle (0.1% DMSO, 0.1% methanol, left
upper), H2O2 (100 mM, right upper), mycophenolic acid (MPA; 10 mM, left lower) and 6-aminonicotinamide (6-AN; 1 mM, right lower). Bar=5 mm. (E)
Quantitative analyses of lysosomal translocation of GAPDH-HT in PC somata treated with CMA activators. Dots of GAPDH-HT in each PC soma were
counted in the center image from the Z-stack. Numbers of GAPDH-HT dots were significantly increased in the presence of CMA activators (H2O2, MPA
and 6-AN). * p,0.01 vs PCs treated with vehicle (unpaired t-test, n=60 for cells treated with vehicle, n=30 for cells treated with CMA activators).
doi:10.1371/journal.pone.0031232.g003
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In contrast to macroautophagy, it remains unclear how CMA
activity is regulated and how CMA relates to various physiological
functions, even though several molecules involved in CMA have
been discovered. While macroautophagy activity can be easily
assessed by the amount and localization of LC3-II [30,31], existing
methods for evaluating CMA activity require special lysosome
isolation techniques or radioisotopic analysis. In addition, these
methods only reflect CMA activity for a large cell population [32],
which has hampered a detailed understanding of CMA. In the
present study, we succeeded in establishing a novel method to
monitor CMA at a single-cell level. Our method enables simple
and real-time observation of CMA activity in single cells and may
represent a breakthrough for elucidating the regulation of CMA
and the role of CMA in normal cellular functions and in disease
pathogenesis.
We believe that GAPDH-HT accumulates in lysosome since
dots of GAPDH-HT colocalize with LAMP2 immunoreactivity
and LysoTracker red fluorescence (Fig. 1 D, E and Fig. 3 B, C).
Figure 4. SCA14 mutant cPKC preferably binds with Hsc70 and suppresses CMA in primary cultured PCs. (A) Schematic illustration of
pull-down assay using the HT system. Resin-conjugated HT ligands covalently bind to cPKC-HT and harvest cPKC-HT and cPKC-binding proteins from
cell lysate. After washes and heat treatment, cPKC-binding proteins are released from the resin, but cPKC-HT itself is still resin-bound through the
covalent linkage between HT and the HT ligand. This is a unique feature of the HT pull-down assay, in contrast to other pull-down assays using
glutathione S-transferase or immunoprecipitation, and enables us to effectively analyze binding partners of the target protein. (B) Representative
silver stained gel of pulled down proteins by the HT pull-down assay and subjected to SDS-PAGE. The HT pull-down assay was conducted using cell
lysate from cerebellar primary cultures that expressed WT or mutant (S119P and G128D) cPKC-HT in PCs. The arrow indicates the protein band that
was more strongly detected in pull-down samples from cell lysates expressing mutant cPKC-HT than in the WT. Mass spectrometric analysis revealed
that this protein is Hsc70. Silver staining gel with pull-down, input and supernatant (Sup) samples is indicated in Figure S5A. (C) Representative
fluorescent images of cPKC-GFP (upper panels) and GAPDH-HT (lower panels) in PC somata 21 h after labeling with TMR-HT ligand. PCs coexpressed
GAPDH-HT and either WT (left), S119P (center) or G128D (right) mutant cPKC-GFP. We evaluated GAPDH-HT lysosomal translocation in PCs not
displaying aggregation of mutant cPKC-GFP. Bar=5 mm. (D) Quantitative analyses of GAPDH-HT lysosomal translocation in PC somata in the absence
(open bars) or presence (hatched bars) of 100 mMH 2O2. Mutant versions of cPKC-GFP (S119P and G128D) significantly decreased the number of
GAPDH-HT dots (* p,0.05, ** p,0.001 vs PCs expressing WT cPKC-GFP without H2O2, unpaired t-test, n=45, and 1 p,0.001 vs PCs expressing WT
cPKC-GFP with H2O2, unpaired t-test, n=45). While H2O2 significantly increased the number of GAPDH-HT dots in PCs expressing WT cPKC-GFP
({ p,0.01, unpaired t-test), it failed to increase the number of GAPDH-HT dots in PCs expressing mutant cPKC-GFP (n.s.: not significant (p.0.05),
unpaired t-test).
doi:10.1371/journal.pone.0031232.g004
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endosomes and lysosomes [33], and LysoTracker stains acidic
organelles including late endosomes and lysosomes [34]. There-
fore, we cannot exclude the possibility that GAPDH-HT
accumulates in late endosomes as well as lysosomes. Recently, it
has been demonstrated that late endosomes are involved in
mammalian microautophagy, in which the delivery of cytosolic
substrates to late endosomes is mediated by Hsc70, but not by
LAMP2A [35]. Therefore, GAPDH-HT might partly accumulate
in late endosomes via microautophagy, which is supported by the
result that siRNA-mediated knockdown of LAMP2A did not
completely inhibit the dot-like accumulation of GAPDH-HT
(Fig. 2B,C). However, because this dot-like accumulation was
highly sensitive to chemicals that affect CMA activity (Fig. 2D–F),
CMA is likely more responsible for this accumulation than Hsc70-
mediated microautophagy.
Reciprocal crosstalk has been reported between CMA and
macroautophagy; when one is impaired, the other is activated to
compensate [29,36]. Similarly, in the present study siRNA-
mediated LAMP2A knockdown activated macroautophagy (Fig.
S2). However, it remains unclear how CMA blockage activates
macroautophagy. Ubiquilin was identified as a candidate to
regulate this crosstalk [37]; it is involved in the formation of
autophagosomes in macroautophagy and is degraded both by
macroautophagy and by CMA. Blockage of CMA would increase
the amount of ubiquilin, leading to the activation of macro-
autophagy. In the present study, we showed that the amount of the
Atg5-Atg12 complex, which is essential for autophagosome
formation [38], was elevated by siRNA-mediated LAMP2A
knockdown (Fig. S2), suggesting that this complex is involved in
the crosstalk between macroautophagy and CMA. Unlike
ubiquilin, Atg5 and Atg12 are not substrates for CMA since they
do not have the KFERQ-like motif required for recognition by
Hsc70 and degradation through CMA [6]. In this scenario, CMA
would affect macroautophagy by regulating other proteins
involved in Atg5 and Atg12 expression, degradation or complex
formation.
In the present study, we evaluated CMA activity in HeLa cells
and primary cultured PCs through dot-like accumulation of
GAPDH-HT. Approximately 60% of HeLa cells expressed
GAPDH-HT dots (Fig. 1C and 2), but almost all PCs had many
dots in somata and dendrites (Fig. 3A). This difference suggests
that CMA activity is higher and more important for removal of
aberrant proteins in nonproliferative neurons than in proliferative
cells. Although most dots were localized to PC somata, several dots
were observed in PC dendrites (Fig. 3A). This suggests that CMA
may participate in the development of dendritic structures or
maintenance of dendritic functions. Further studies are necessary
to elucidate the role of CMA in PC dendrites.
In the present study, we demonstrated that the SCA14 mutant
cPKC preferentially interacts with Hsc70 and impairs CMA in
primary cultured PCs. cPKC has three KFERQ-like motifs in its
amino acid sequence (QLEIR at residues 162–166, LKLDN at
481–485 and NFDKF at 642–646). Therefore, it is possible that a
strong interaction between mutant cPKC and Hsc70 hampers
the binding of other CMA substrates to Hsc70 and thus inhibits
their degradation. In the present study, 2-color FRAP analysis
revealed that mutant cPKC-GFP increased the mobility of
GAPDH-HT in living PCs (Table S1). This observation may be
explained if Hsc70 were prevented from interacting with
GAPDH, so that GAPDH would be released from a GAPDH-
Hsc70 complex. Since CMA is involved in adaptation to stress
conditions [7,29], CMA impairment by mutant cPKC could
exacerbate cellular vulnerability to various cellular stresses such
as oxidative stress and contribute to neurodegeneration of PCs in
SCA14.
We used GAPDH as a CMA substrate to monitor CMA
activity, since it has been widely used for CMA studies [6,7].
Although the lysosomal translocation of GAPDH-HT was
significantly inhibited by mutant cPKC (Fig. 4 and Fig. S7A,B),
it did not affect the total amount of GAPDH (Fig. S7C,D). Since
GAPDH is a key enzyme in glycolysis, the amount of GAPDH
might be strictly regulated by transcriptional level as well as
degradation through CMA. Indeed, we found that total GAPDH
amount was not affected by siRNA-mediated LAMP2A knock-
down (Fig. S7E,F). Similar findings were also reported by Vogiatzi,
et al [39]. Instead, we confirmed CMA inhibition by mutant
cPKC through the significant increase of another CMA substrate,
MEF2D (Fig. S7C,D), which is reported to be elevated by the
knockdown of LAMP2A [10].
Several studies have demonstrated that CMA is involved in the
pathogenesis of Parkinson’s disease [8,9,10,11] and Alzheimer’s
disease [12,13]. Our novel CMA monitoring method can be
available for further and precise elucidation of the involvement of
CMA in neural function and in the pathogenesis of neurodegen-
erative diseases. Indeed, we succeeded to reveal the alteration of
CMA activity by a mutant protein causing neurodegenerative
disease in a single neuron level. Moreover, selective CMA
degradation of expanded polyglutamine alleviates the pathology
and phenotype in a mouse model of Huntington’s disease [40].
Elucidation of CMA function would raise the possibility that CMA
is a novel therapeutic target for neurodegenerative diseases. Our
method is also available as a screening tool for chemicals that
affect CMA activity, and thus could facilitate the discovery of
novel CMA-targeted therapeutics for neurodegenerative diseases
and help elucidate the role of CMA in normal and pathogenic
processes.
Materials and Methods
Materials
Dulbecco’s modified Eagle medium (DMEM), mycophenolic
acid, SB202190 and MISSION siRNA universal negative control
(nontargeting-siRNA) were obtained from Sigma-Aldrich. The
SUMITOMO Nerve-Cell Culture System (Neuron culture
medium and dissociation solutions) was from Sumitomo Bakelite
(Tokyo, Japan). Penicillin/streptomycin solution, hydrogen per-
oxide and cycloheximide were from Nakalai Tesque (Kyoto,
Japan). Tokyo Chemical Industry (Tokyo, Japan) supplied 6-
aminonicotinamide. The HaloTag system (HaloTag vector and
HaloTag ligand) was from Promega (Madison, WI). Fluorescein
isothiocyanate (FITC)-conjugated donkey anti-rat IgG antibody
was from Jackson ImmunoResearch Laboratories (West Grove,
PA). Anti-human LAMP2 mouse monoclonal and anti-mouse
LAMP2 rat monoclonal antibodies were from the developmental
studies hybridoma bank (Iowa, IA). Anti-mouse LAMP2A rabbit
polyclonal antibody and AlexaFluor 488 (Alexa488)-conjugated
goat anti-mouse IgG and anti-rabbit IgG antibodies, normal goat
serum (NGS), LysoTracker red, Lipofectamine RNAiMAX and
Hank’s balanced salt solution were from Invitrogen (Carlsbad,
CA). Anti-human/mouse LAMP2A rabbit polyclonal antibody
was from Abcam (Cambridge, UK). Glass-bottomed culture dishes
(35-mm diameter) were from MatTek (Ashland, MA). Materials
for supporting figures and tables were listed in Methods S1.
Cell culture
HeLa cells were purchased from Riken Cell Bank (Tsukuba,
Japan). HeLa cells were cultured in DMEM supplemented with
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100 mg/ml of streptomycin in a humidified atmosphere containing
5% CO2 at 37uC. Mouse cerebellar primary culture was prepared
using SUMITOMO Nerve-Cell Culture System according to the
manufacturer’s protocol [18]. Briefly, cerebella of E14 embryos
from pregnant ICR mice were dissociated using dissociation
solutions and were cultured in the neuron culture medium for 21–
30 days in vitro (DIV). This experiment was conducted according to
the guideline of animal use and approved by the animal care and
use committee of Hiroshima University (permit number: A08-68).
Adenoviral vectors using a tetracycline (Tet)-regulated
system
We constructed two types of adenoviral vectors to express the
target proteins (GFP- and HT-fused proteins) under the regulation
of tetracycline [41] (Fig. S1). The first vector expresses the
tetracycline transactivator (tTA) under the control of the
cytomegalovirus (CMV) promoter for HeLa cells (Ad-CMV-tTA)
or the L7 promoter for primary cultured PCs (Ad-L7-tTA). The
second vector expresses the target protein under the control of the
TetOp minimal promoter, which is activated by tTA (Fig. S1). Use
of the first and second vectors in combination enables cell type-
specific expression of target proteins.
Ad-CMV-tTA, Ad-L7-tTA, Ad-TetOp-cPKC-GFP (wild type
(WT), S119P and G128D mutant) and Ad-TetOp-GAPDH-HT
were constructed using the AdEasy adenoviral vector system
(Stratagene, La Jolla, CA) according to the manufacturer’s
protocol, as previously described [18].
Observation of lysosomal translocation of GAPDH-HT
proteins
HeLa cells (1610
5 cells/glass-bottomed culture dish) were
infected with Ad-CMV-tTA (MOI of 10) and Ad-TetOp-
GAPDH-HT (MOI of 10) 1 day after cell spread and cultured
for an additional 2–3 days. Cells were incubated with culture
medium containing 500 nM TMR-HT ligand for 10 min at 37uC,
followed by 3 washes with culture medium. Cells were fixed with
4% paraformaldehyde in PBS immediately after labeling or after
21 h of cultivation. In some experiments, cells were treated with
culture medium containing vehicle (0.1% DMSO and 0.1%
methanol), CMA activator (serum deprivation, 100 mMH 2O2 or
10 mM mycophenolic acid) or CMA inhibitor (20 mM SB202190
or 20 mg/ml cycloheximide). Lysosomal translocation of GAPDH-
HT was assessed by its colocalization with LAMP2, LAMP2A or
LysoTracker-red. LAMP2 and LAMP2A were immunostained
with anti-human LAMP2 monoclonal antibody (diluted 1:3000)
and anti-LAMP2A rabbit polyclonal antibody (1:200), respective-
ly, followed by Alexa488-conjugated goat anti-mouse and anti-
rabbit IgG antibodies (1:500), respectively, as described previously
[19]. To further confirm lysosomal localization of GAPDH-HT, it
was labeled with OG, and cells were stained with 25 nM
LysoTracker red, a lysosomal marker, for 30 min before fixation.
Fluorescent images were obtained using a confocal microscope
(LSM510META, Carl Zeiss, Oberkochen, Germany). Cells
having more than 5 dots were classified as GAPDH-HT dot-
positive cells. We quantitatively evaluate lysosomal accumulation
of GAPDH-HT by the percentage of GAPDH-HT dot-positive
cells in 50–70 GAPDH-HT expressing cells per culture. For
further assessment of lysosomal accumulation, we counted the
number of GAPDH-HT dots per 40–100 independent GAPDH-
HT-expressing cells.
Cerebellar primary cultures (2610
5 cells/glass-bottomed culture
dish) were infected with Ad-L7-tTA (MOI of 20) and Ad-TetOp-
GAPDH-HT (MOI of 3) and/or Ad-TetOp-cPKC-GFP (MOI of
3) on DIV20–22 and cultured for 7 days. Living cells were
incubated with 500 nM of TMR-HT ligand for 10 min at 37uC.
After 4 washes with culture medium, cells were cultured for 21 h
in the presence or absence of various compounds and fixed with
4% paraformaldehyde in PBS. LAMP2 was immunostained with
anti-mouse LAMP2 rat monoclonal antibody (1:100), followed by
FITC-conjugated donkey anti-rat IgG (1:400) antibody. Fluores-
cent images of whole PCs and PC somata were obtained as a Z-
stack of images using a confocal microscope. We quantitatively
evaluated lysosomal accumulation of GAPDH-HT by the number
of cytoplasmic dots per PC soma. We counted the number in the
center image of the Z-stack from somata of 30–60 independent
PCs.
Pull-down assay using the HaloTag system
A cerebellar primary culture (4610
5 cells/3.5 cm culture dish)
was infected with Ad-L7-tTA at a multiplicity of infection (MOI)
of 20 and Ad-TetOp-cPKC-HT (MOI of 3) on DIV14 and
cultured for 14 days. Cells were harvested and lysed in lysis buffer
(1% Triton X-100 in PBS containing 20 mg/ml of leupeptin,
1 mM phenylmethanesulfonyl fluoride (PMSF), 1 mM NaF,
100 nM Calyculin A). Cell lysates were cleared by centrifugation
for 15 min at 15,0006ga t4 uC and rotated with 30 ml of HaloLink
resin (resin fused with HT ligand) for more than 8 h at 4uC. After
3 PBS washes of the resin, proteins bound to cPKC-HT were
eluted in sample buffer (3% SDS, 2% 2-mercaptoethanol, 5%
glycerol, 0.002% bromophenol blue, 92 mM Tris-HCl, pH 6.8)
by heating (95uC for 3 min). Pulled down proteins, input (10%)
and supernatant (10%) after pull-down were subjected to SDS-
PAGE using gradient (5–20%) acrylamide gel, and the separated
proteins were visualized by silver staining. Specific protein bands
were excised from the gel and subjected to mass spectrometry
analysis.
siRNA
Nontargeting-siRNA was used as a negative control of siRNA
transfection. siRNAs against human LAMP2A (sense: 59-GG-
CAGGAGUACUUAUUCUAGU-39, antisense: 59-UAGAAUA-
AGUACUCCUGCCAA-39) and human Atg5 (sense: 59-CA-
CUUUCAGAAGGUUAUGAGA-39, antisense: 59-UCAUAAC-
CUUCUGAAAGUGCU-39) were constructed by Hayashi-kasei
(Osaka, Japan). siRNA (50 pmol) was transfected to HeLa cells 1
day after cell spread using Lipofectamine RNAiMAX. The culture
medium was exchanged 4 h after transfection. To express
GAPDH-HT in siRNA-transfected cells, adenoviral vectors were
added to the medium used for the exchange.
Supporting Information
Methods S1 Materials for supporting figures and ta-
bles.
(DOCX)
Figure S1 Schematic diagram of the tetracycline (Tet)-
regulated adenoviral expression system. We used two
types of adenoviral vectors to express cPKC-GFP using the
tetracycline (Tet)-regulated gene expression system. The first type
of vector was constructed to express the tetracycline transactivator
(tTA). Cell lines (HeLa and MEF cells) were infected with Ad-
CMV-tTA, which expresses tTA under the control of the CMV
promoter. Primary-cultured cerebellar Purkinje cells were infected
with Ad-L7-tTA expressing tTA under the control of the L7
promoter, which induces gene expression in a PC-specific manner.
The second type of vector, Ad-TetOp-target protein (GFP- and
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control of the TetOp minimal promoter, which is transactivated
by tTA. Upon co-infection with these two adenoviral vectors, tTA
binds to the TetOp promoter and activates the transcription of the
target protein. The expression of GFP- and HT-fused proteins is
controlled by the promoter in the first adenoviral vector. In the
presence of Tet, expression of the target protein is turned off, since
Tet-bound tTA is unable to bind the TetOp promoter.
(TIF)
Figure S2 Immunoblotting and LC3 immunostaining of
HeLa cells transfected with LAMP2A- and Atg5-siRNA.
(A) Representative immunoblots of HeLa cells transfected with
nontargeting (Non)-, LAMP2A- and Atg5-siRNAs, detected with
anti-LAMP2A, LAMP2, Atg5, LC3 and b-tubulin antibodies.
Cells were harvested and analyzed 3 days after siRNA transfec-
tion. The anti-Atg5 antibody detected an Atg5-Atg12 complex at
about 55 kDa. The LC3 antibody detected LC3-I (19 kDa) and
LC3-II (16 kDa). (B) Quantitative analyses of immunoblotting
data shown in A. The amount of each protein was normalized to
the amount of b-tubulin. * p,0.05, ** p,0.01 and *** p,0.001 vs
cells treated with nontargeting-siRNA (unpaired t-test, n=3 in
LAMP2, n=5 in other proteins). (C) Representative LC3
immunostaining of HeLa cells transfected with nontargeting-
(left), LAMP2A- (center) and Atg5- (right) siRNAs. Bar=20 mm.
(TIF)
Figure S3 Lysosomal translocation of GAPDH-HT in
cells with inhibited macroautophagy. (A) Representative
fluorescent images of GAPDH-HT 21 h after labeling with TMR-
HT ligand in HeLa cells transfected with nontargeting-siRNA (left)
and Atg5-siRNA (right). Bar=20 mm. (B) Quantitative analyses of
GAPDH-HT lysosomal translocation in HeLa cells transfected
with nontargeting (Non)- and Atg5-siRNAs. Percentages of
GAPDH-HT-dot-positive cells were not significantly affected by
siRNA-mediated knockdown of Atg5 (unpaired t-test, n=16). (C)
Representative fluorescent images of GAPDH-HT in HeLa cells
treated with vehicle (0.1% DMSO, 0.1% methanol, left) or 3-
methyladenine (3-MA; 10 mM, right) taken 21 h after labeling
with TMR-HT ligand. Bar=20 mm. (D) Quantitative analyses of
GAPDH-HT lysosomal translocation in HeLa cells treated with 3-
MA. Percentages of GAPDH-HT dot-positive cells were not
significantly affected by 3-MA (unpaired t-test, n=12 for cells
treated with vehicle, n=8 for cells treated with 3-MA). (E)
Representative GAPDH-HT fluorescence (left), LAMP2A immu-
nostaining (center) and merged (right) images of Atg5-KO MEF
cells 21 h after labeling with TMR-HT ligand. Dots of GAPDH-
HT strongly colocalized with LAMP2A-positive lysosomes.
Bar=10 mm.
(TIF)
Figure S4 Immunostaining of LC3 and LAMP2A in HeLa
cells displaying GAPDH-HT dots in the presence or
absence of CMA activators. (A) Representative GAPDH-HT
fluorescence (upper panels), LC3 immunostaining (center panels)
and merged (lower panels) images of HeLa cells treated with
vehicle (0.1% DMSO, 0.1% methanol), serum free medium (0.1%
DMSO, 0.1% methanol), H2O2 (100 mM) or MPA (10 mM) 21 h
after labeling with TMR-HT ligand. While LC3-positive dots that
represent autophagosomes were distributed diffusely in the
cytoplasm, GAPDH-HT dots accumulated in the perinuclear
region in the absence or presence of CMA activators. Bar=5 mm.
(B) Higher magnification images of squares in merged images of
serum (2) (upper) and H2O2 (lower) treatments. Although serum
deprivation and H2O2 increased the number of LC3-positive dots,
these dots rarely colocalized with GAPDH-HT dots, suggesting
that GAPDH-HT dots do not result from macroautophagy. (C)
Representative GAPDH-HT fluorescence (upper panels), LC3
immunostaining (center panels) and merged (lower panels) images
of HeLa cells treated with vehicle, serum free medium, H2O2 or
MPA 21 h after labeling with TMR-HT ligand. Bar=5 mm. (D)
Higher magnification images of squares in merged images of
serum (2) (upper) and H2O2 (lower) treatments. GAPDH-HT dots
colocalized with or were surrounded by LAMP2A-positive dots in
the absence or presence of CMA activators, indicating that
lysosomal translocation of GAPDH-HT is mediated by CMA.
(TIF)
Figure S5 Lysosomal translocation of GAPDH-HT was
inhibited by siRNA-mediated knockdown of LAMP2A in
primary rat cortical neurons. (A) Representative fluorescence
images of GAPDH-HT 21 h after labeling with TMR-HT ligand
in cortical neurons transfected with nontargeting-siRNA (left) or
LAMP2A-siRNA (right). Bar=5 mm. (B) Quantitative analyses of
lysosomal translocation of GAPDH-HT in cortical neuron somata
transfected with nontargeting (Non)- and LAMP2A-siRNA. Dots
of GAPDH-HT in each soma were counted in the center image
from the Z-stack. Numbers of GAPDH-HT dots were significantly
decreased by siRNA-mediated LAMP2A-knockdown. ** p,0.001
vs cells treated with nontargeting-siRNA (unpaired t-test, n=30).
(C) Representative immunoblots of primary rat cortical neurons
transfected with nontargeting (Non)- and LAMP2A-siRNA,
detected with anti-LAMP2A and b-tubulin antibodies. Cells were
harvested and analyzed 3 days after siRNA transfection. We
confirmed that the amount of LAMP2A was strongly decreased by
siRNA-mediated LAMP2A-knockdown in primary rat cortical
neurons.
(TIF)
Figure S6 Preferred interaction of mutant cPKC with
Hsc70 by HT pull-down assay. (A) Representative silver
stained gel of proteins obtained by the HT pull-down assay. The
HT pull-down assay was conducted using cell lysate from
cerebellar primary cultures that expressed WT or mutant
(S119P and G128D) cPKC-HT in PCs. Input and supernatant
(Sup) indicate cell lysates before and after pull-down with HT
ligand-conjugated resin, respectively. The arrow indicates the
protein band that was more strongly detected in pull-down
samples from cell lysates expressing mutant cPKC-HT than in the
WT. (B) Representative immunoblots of pull-down, input (5%)
and Sup (5%) samples obtained by HT pull-down assay from SH-
SY5Y cells expressing WT and mutant cPKC-HT. Samples were
subjected to SDS-PAGE with 8% acrylamide gel, followed by
immunoblotting with anti-HT (for cPKC-HT,), anti-Hsc70 and
anti-b-tubulin antibodies. Hsc70 was strongly detected in pulled
down samples with mutant cPKC-HT, compared with WT
cPKC-HT, suggesting preferred binding of Hsc70 with mutant
cPKC. In contrast, b-tubulin was similarly detected in pull down
samples with WT and mutant cPKC-HT. Since pulled down
proteins that bound with HaloLink resin were not released from
resin in principal (Fig. 4A), the amount of pulled down proteins
was estimated the difference in the band densities between input
and Sup. However, cPKC-HT was also detected in pull down
samples. This would be reflected by the self-association of pulled
down cPKC-HT with that left in lysates. (C) Representative
immunoblots of pull-down, input (5%) and Sup (5%) samples
obtained by HT pull-down assay from SH-SY5Y cells expressing
Hsc70-HT and WT/mutant cPKC. Expression of corresponding
proteins were detected with anti-HT (for Hsc70-HT), anti-cPKC
and anti-b-tubulin antibodies. Stronger cPKC-immunoreacitve
bands were detected in pulled down samples from mutant cPKC-
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down samples from mutant cPKC-coexpressing cells, an addi-
tional lower band was detected, compared with samples from
cPKC-coexpressing cells. This would represent unphosphorylated
mutant cPKC, since mutant cPKC was less phosphorylated [17].
This suggests that Hsc70 binds preferably with unphosphorylated
mutant cPKC.
(TIF)
Figure S7 SCA14 mutant cPKC suppresses CMA activity
in cultured cell lines. (A) Representative fluorescent images of
cPKC-GFP (upper panels) and GAPDH-HT (lower panels) in
HeLa cells 21 h after labeling with TMR-HT ligand. HeLa cells
coexpressed GAPDH-HT and WT (left), S119P (center) or G128D
(right) mutant cPKC-GFP. Lysosomal translocation of GAPDH-
HT was inhibited by mutant cPKC-GFP in cells with and without
aggregation of mutant cPKC-GFP. Bar=20 mm. (B) Quantitative
analyses of GAPDH-HT lysosomal translocation in HeLa cells.
Mutant cPKC-GFPs (S119P and G128D) significantly decreased
the number of GAPDH-HT dots (* p,0.01, ** p,0.001 vs cells
expressing WT cPKC-GFP, n=4, unpaired t-test), while there
was no difference in lysosomal translocation between cells
expressing GFP and WT cPKC-GFP. (C) Representative immu-
noblots of SH-SY5Y cells expressing WT and two mutant (S119P
and G128D) forms of cPKC-GFP, detected with anti-GFP, anti-
GAPDH, anti-MEF2D and anti-a-tubulin antibodies. Cells were
harvested and analyzed 24 h after transduction with cPKC-GFP
expression adenovirus. (D) Quantitative analyses of immunoblot-
ting data shown in C. The amounts of GAPDH and MEF2D
were normalized to the amount of a-tubulin. ** p,0.01 and
*** p,0.001 vs cells expressing WT cPKC-GFP (unpaired t-test,
n=5). (E) Representative immunoblots of HeLa cells transfected
with nontargeting (Non)- and LAMP2A-siRNAs, detected with
anti-LAMP2A, GAPDH and b-tubulin antibodies. Cells were
harvested and analyzed 3 days after siRNA transfection. (F)
Quantitative analyses of immunoblotting data shown in E (n=5).
The amount of GAPDH was normalized to the amount of b-
tubulin.
(TIF)
Table S1 Results of 2-color FRAP analysis in primary
cultured PCs expressing cPKC-GFP and HT-fused
proteins (Hsc70-HT, HT, GAPDH-HT). FRAP analysis
was conducted immediately after labeling with TMR-HT ligand
in PC somata not displaying aggregation of mutant cPKC-GFP.
The half time of fluorescence recovery is inversely correlated with
the mobility of a GFP- or HT-fused protein. The recovery half
time of mutant cPKC-GFP was markedly longer than that of WT
cPKC-GFP, probably due to oligomer formation [18]. The
recovery half time of Hsc70-HT was significantly prolonged by
coexpression with mutant cPKC-GFP, while the recovery half
time of HT alone was not affected by the presence of mutant
cPKC-GFP. These findings suggest that the mobility of Hsc70 is
decreased due to a strong interaction with mutant cPKC in living
PCs. On the contrary, the recovery half time of GAPDH-HT was
significantly shortened by the presence of G128D mutant cPKC-
GFP. * p,0.05, ** p,0.01, *** p,0.001 vs WT cPKC-GFP-
expressing cells, unpaired t-test.
(TIF)
Table S2 Results of RICS analysis in primary cultured
PCs expressing cPKC-GFP and HT-fused proteins
(Hsc70-HT, HT). RICS analysis was conducted immediately
after labeling with TMR-HT ligand in PC somata not displaying
aggregation of mutant cPKC-GFP. The diffusion coefficient
represents the mobility of GFP- and HT-fused proteins. The
diffusion coefficient of mutant cPKC-GFP was markedly de-
creased from that of WT cPKC-GFP, probably due to oligomer
formation [18]. The diffusion coefficient of Hsc70-HT was slightly
but significantly decreased by coexpression of mutant cPKC-GFP,
while the diffusion coefficient of HT was not affected by mutant
cPKC-GFP, suggesting that the mobility of Hsc70 was reduced in
the presence of mutant cPKC. Relative cross-correlation repre-
sents the percentage of fluorescent molecules that bind to
molecules labeled with the other fluorophore. The relative cross-
correlations of mutant cPKC-GFP and Hsc70-HT both signifi-
cantly increased, compared with cells coexpressing WT cPKC-
GFP and Hsc70-HT. These findings suggest that mutant cPKC
strongly interacts with Hsc70 and reduces its mobility in living
PCs. * p,0.05, ** p,0.01, *** p,0.001 vs WT cPKC-GFP-
expressing cells, unpaired t-test.
(TIF)
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